InfraReDx Announces Research Collaboration With Massachusetts General Hospital To Explore New Generation Of Cardiovascular Imaging Devices

BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx, Inc., a cardiovascular imaging company pioneering the personalized diagnosis of coronary artery disease, today announced a collaboration with Massachusetts General Hospital (MGH) and leading coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. Dr. Tearney is best known for pioneering research efforts developing Optical Coherence Tomography (OCT), an imaging technology that uses light-scattering to image coronary arteries. Infraredx and Dr. Tearney first collaborated over a decade ago on the development of the company’s near-infrared spectroscopy (NIRS) technology, which is now integrated into the company’s dual-modality intravascular TVC Imaging System™. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS).

Help employers find you! Check out all the jobs and post your resume.